Zonagen

Blame Viagra.

For months, shorts have been jumping on Zonagen (ZONA Quote), a Texas company that makes an impotence pill that even the company admits is unlikely to be anything more than a poor relation to the now-famous riser from Pfizer (PFE Quote).

But since the beginning of the year, Zonagen has been invigorated, with the stock's 103% rise topping Pfizer's 48%. Still, the company's market cap of about $420 million is less than 0.5% of Pfizer's market cap. And, with Viagra's success off the charts, even diehard bears are now worried that Zonagen's run may continue for a while. Right now the stock isn't trading solely on the prospects for its drug's approval and market success, but the underlying impotence pill story. In a story-stock market, this means pain for the shorts. ...